10-Q: Shattuck Labs Narrows Losses, Boosts Capital with Private Placement

Shattuck Labs reported a significant reduction in net loss for Q3 and the nine months ended September 30, 2025, driven by decreased R&D and G&A expenses, while securing $45.7 million in a private placement.

Summary

• Net loss for the three months ended September 30, 2025, decreased to $10,056,000 from $16,675,000 in the prior year, a 39.7% improvement.
• Net loss for the nine months ended September 30, 2025, decreased to $36,216,000 from $56,731,000 in the prior year, a 36.2% improvement.
• Research and development expenses decreased by 53.3% to $7,618,000 for Q3 2025 and by 49.4% to $26,218,000 for the nine months ended September 30, 2025, primarily due to the discontinuation of SL-172154 and workforce reductions.
• General and administrative expenses decreased by 11.0% to $4,098,000 for Q3 2025 and by 12.9% to $12,919,000 for the nine months ended September 30, 2025, also due to workforce reductions and reduced legal expenses.
• Secured $45,700,000 in gross proceeds from a private placement in August 2025, involving common stock, pre-funded warrants, and common stock warrants.
• Cash and cash equivalents, along with short-term investments, totaled $86,100,000 as of September 30, 2025, projected to fund operations for at least the next twelve months.
• Management believes current liquidity plus potential warrant exercise proceeds will fund operations into 2029.
• Initiated enrollment in the Phase 1 clinical trial for SL-325, a lead program for inflammatory bowel disease (IBD).
• Regained compliance with Nasdaq's minimum bid price requirement on September 16, 2025.

Sentiment

Score: 7

Explanation: The company demonstrated improved financial efficiency with reduced losses and a significant capital raise, extending its cash runway. The advancement of its lead program SL-325 into Phase 1 is a positive step. However, revenue decline, reliance on future warrant exercises, and external regulatory/macroeconomic risks temper the overall sentiment.

Positives

• Significant reduction in net loss for both the quarter and nine-month period, indicating improved financial efficiency.
• Substantial decrease in R&D and G&A expenses, reflecting successful cost management and strategic program prioritization.
• Successful private placement raising $45,700,000, significantly bolstering capital resources.
• Projected liquidity runway extended into 2029, assuming full exercise of outstanding common stock warrants.
• Initiation of Phase 1 clinical trial for lead candidate SL-325, advancing the pipeline.
• Regained compliance with Nasdaq's minimum bid price requirement, resolving a listing concern.
• Preclinical data for SL-325 suggests a potentially first-in-class DR3 antagonist antibody with a favorable safety profile and extended dosing intervals.
• Kayak Agreement provides potential future milestone payments up to $86,000,000 and tiered royalties.

Negatives

• License and collaboration revenue decreased significantly by 66.6% for Q3 2025 and 82.5% for the nine months ended September 30, 2025, due to the completion of prior collaboration agreements.
• Continued accumulated deficit of $417,936,000 as of September 30, 2025, and ongoing net losses and negative cash flows from operations.
• Discontinuation of clinical development for SL-172154 in October 2024.
• Dependence on a limited number of CDMOs and CROs for drug product supply and clinical trial management.
• ATM Facility is currently unavailable due to an expired S-3 registration statement and public float limitations.
• Uncertainty regarding the exercise of common stock warrants, which could impact expected cash proceeds.

Risks

• Inability to obtain additional funding on acceptable terms, or at all, which could force delays, reductions, or elimination of product development programs.
• Reliance on assumptions for liquidity estimates, which may prove wrong, leading to a need for additional funds sooner than expected.
• Uncertainty of common stock warrant exercise, including potential cashless exercises, which could reduce anticipated cash proceeds and adversely affect liquidity.
• Disruptions at the FDA and other government agencies (e.g., government shutdowns, mass layoffs, leadership changes, budget reductions) could negatively affect regulatory review timelines and approvals.
• Impact of current and future laws and regulations, such as the Inflation Reduction Act (IRA) and potential tariffs on imported pharmaceuticals (e.g., 100% tariffs announced in September 2025), which could increase costs or affect pricing and reimbursement.
• Adverse effects from global macroeconomic conditions, including inflation, slower growth, fluctuating interest rates, changes in trade policies, supply chain weaknesses, financial institution instability, and geopolitical events.
• Inability to generate significant product revenue unless and until product candidates successfully complete development, obtain regulatory approval, and are sold, which is expected to take several years.
• Potential for unexpected results from nonclinical studies and clinical trials, leading to discontinuation, delay, or modification of programs.
• Challenges in retaining key executives and hiring/retaining qualified professionals.
• Risks related to intellectual property protection, potential need for third-party licenses, and ability to enter into strategic collaborations.

Future Outlook

The company expects to continue incurring significant expenses and operating losses in the near term as it advances preclinical and Phase 1 clinical development of SL-325, initiates studies for additional product candidates, and maintains operational infrastructure. It does not anticipate generating significant product revenue until successful development, regulatory approval, and commercialization of its product candidates, which is expected to take several years. Management believes current cash and investments, combined with potential warrant exercise proceeds, will fund operations into 2029.

Management Comments

• "We believe that the underlying biological differences in the expression of DR3 and TL1A, and the design characteristics of SL-325, may allow SL-325 to achieve best-in-class clinical remission rates in patients with IBD due to a more complete and durable blockade of the clinically validated DR3/TL1A pathway."
• "The lack of toxicity of SL-325 in our recently completed non-human primate (NHP) toxicology study also suggests a potentially favorable clinical safety profile."
• "Because DR3 is a membrane-restricted target, immune complex formation is not expected either for SL-325, SL-425, or DR3 directed bispecific antibodies."
• "We are planning initial clinical development of SL-325 for patients with IBD, including UC and/or CD."
• "We expect to complete enrollment in the full Phase 1 clinical trial in the second quarter of 2026."
• "We expect to continue to incur significant expenses and operating losses in the near term in connection with our ongoing activities."
• "We believe that our cash and cash equivalents and short-term investments as of September 30, 2025, and the potential future proceeds assuming the full exercise of all outstanding common stock warrants will be sufficient to fund projected operations into 2029."

Industry Context

Shattuck Labs operates in the highly competitive and capital-intensive biotechnology sector, focusing on inflammatory and immune-mediated diseases. Its lead candidate, SL-325, targets the DR3/TL1A pathway, a clinically validated mechanism for inflammatory bowel disease (IBD). The company's strategy to target DR3 directly, rather than TL1A, aims to overcome limitations observed with TL1A blocking antibodies, such as immune complex formation and immunogenicity seen with bispecific antibodies like AMG966. The industry is seeing a trend towards multi-pathway blockade for complex diseases like IBD, and Shattuck's development of DR3 bispecific antibodies aligns with this trend. The recent enactment of the OBBBA, which broadens orphan drug exemptions from Medicare price negotiation, could be a favorable development for future product pricing, while broader macroeconomic instability and potential tariffs on imported pharmaceuticals pose industry-wide challenges.

Comparison to Industry Standards

• SL-325's preclinical studies showed it blocked TL1A binding to DR3 better than sequence equivalents of leading TL1A blocking antibodies, suggesting a potential competitive advantage in efficacy.
• The company highlights that the clinical safety profile of TL1A blocking antibodies generated by other parties derisks the clinical safety profile for DR3 blockade, implying SL-325's safety profile is expected to be comparable or better.
• The design of SL-325 to avoid Fc gamma receptor binding and immune complex formation addresses a known issue (immunogenicity) observed in other bispecific antibodies targeting TL1A, such as AMG966, which was discontinued after Phase 1 due to high-titer neutralizing ADA responses.
• The stable expression of DR3 and SL-325's durable binding, suggesting blockade for at least one month, indicates potential for extended dosing intervals, which could offer a convenience advantage over competitors requiring more frequent administration.
• The distinct expression patterns of DR3 and TL1A in IBD patients, with DR3 being more abundant in both inflamed and non-inflamed tissue, positions SL-325 to potentially achieve higher rates of clinical and endoscopic remission compared to TL1A blocking antibodies that may be less effective in non-inflamed areas.

Corporate Governance

Related Party Transactions

• Two 10% beneficial owners of common stock participated in the August 2025 private placement offering, purchasing 8,963,785 pre-funded warrants and receiving accompanying common stock warrants to purchase an additional 8,963,785 shares of common stock, on the same terms as other participants.

Stakeholder Impact

• Shareholders: Dilution from the August 2025 private placement (issuance of common stock, pre-funded warrants, and common stock warrants). Potential for further dilution if common stock warrants are exercised. Increased liquidity runway provides stability. Regaining Nasdaq compliance reduces delisting risk.
• Employees: Workforce reductions in 2024 due to discontinuation of SL-172154 impacted personnel-related expenses. Stock-based compensation remains a component of employee remuneration.
• Customers/Collaborators: Completion of obligations under Ono and ImmunoGen agreements means no further revenue from these. New Kayak Agreement provides potential future milestones and royalties.
• Creditors: Improved liquidity from capital raise enhances the company's ability to meet short-term obligations.
• Suppliers/CDMOs/CROs: Continued reliance on a limited number of third-party service providers for R&D and clinical trials, posing supply chain and operational risks.

Next Steps

• Complete enrollment in the full Phase 1 clinical trial for SL-325 by Q2 2026.
• Further characterize the receptor occupancy (RO) and pharmacokinetic (PK) profile of SL-325 in the Phase 1 clinical trial to confirm extended dosing intervals.
• Explore the efficacy of SL-325 in other inflammatory and immune-mediated diseases in future clinical trials.
• Initiate nonclinical studies and clinical trials for additional product candidates, including potential bispecific DR3 antagonist antibody product candidates.
• Manufacture sufficient quantities of bulk drug substance and drug product to support ongoing and planned nonclinical studies and clinical trials.
• File a new Registration Statement on Form S-3 to reactivate the ATM Facility.
• Continue to develop, perfect, and defend its intellectual property portfolio.
• Assess the full impact of the One Big Beautiful Bill Act (OBBBA) provisions effective through 2027.

Key Dates

Recommendation

Shattuck Labs has demonstrated improved financial discipline by significantly reducing its net loss and operating expenses. The successful private placement has substantially strengthened its balance sheet and extended its cash runway into 2029, providing crucial stability for its ongoing drug development. The advancement of SL-325 into Phase 1 clinical trials for IBD is a positive step, and its preclinical profile suggests a potentially differentiated mechanism. However, the company remains in a clinical-stage phase with no commercial products, and future revenue generation is highly uncertain and years away. The significant decrease in collaboration revenue highlights the reliance on new partnerships. Furthermore, the uncertainty surrounding the exercise of common stock warrants, the unavailability of the ATM facility, and broader macroeconomic and regulatory risks (like the government shutdown impacting FDA) introduce considerable headwinds. While the financial position has improved, the long development timelines, inherent risks of clinical trials, and external market factors suggest a 'hold' recommendation. Investors should monitor SL-325's clinical trial progress and the company's ability to secure additional non-dilutive partnerships or further capital efficiently.

Keywords

Shattuck Labs, STTK, biotechnology, clinical-stage, SL-325, DR3 antagonist, inflammatory bowel disease, IBD, Phase 1 clinical trial, private placement, capital raise, Nasdaq compliance, biopharmaceutical, drug development, oncology, TRIM7 program, Kayak Therapeutics, SEC filing, 10-Q, financial results